Awardee OrganizationCOLLEGE OF MEDICINE, UNIVERSITY OF LAGOS
Description
Abstract Text
Project Summary
This application presents a five-year career development and research program for an early career investigator
from Nigeria. The candidate, Kehinde Okunade, is a 2018 Fogarty fellow through the HBNU FIC D43 Training
Program and also a Senior Lecturer in Obstetrics and Gynecology at the College of Medicine of the University
of Lagos in Nigeria. The goals of his application are to use the protected time provided through the program to
(1) Build and strengthen mentoring relationships and skills transfer through regular interactions with mentors
and co-mentors; (2) Acquire experiential skills in clinical epidemiologic research and be able to translate this to
public health practice (3) Conduct the rigorous research proposed in the application; (4) Acquire skills in the
design and conduct of end-to-end clinical trials; (5) Establish research collaboration network and effectively
coordinate multidisciplinary research projects, and (6) Be able to write, secure, and manage grants to conduct
studies as well as write manuscripts for publication in high-impact journals.
The proposed research in the FIC K43 application, “COMParative ASSessment of p16/Ki-67 DUal Staining
Technology in women living with HIV (COMPASS-DUST)” is the first in sub-Saharan Africa (sSA) that aims to
evaluate the performance of p16/Ki-67 dual staining technology (DUST) in cervical cancer screening among
women living with HIV (WLHIV). In Aim 1 and 2, using an intra-participant comparative study design, we will
enrol n=300 sexually active WLHIV aged 25–65 years at two accredited adult HIV treatment centres in Lagos,
Nigeria to compare the performance of DUST to the currently used screening methods (Pap smear, hr-HPV
DNA, or VIA testing) in detecting high-grade cervical intraepithelial neoplasia (CIN2/3). In Aim 3, we will use a
prospective cohort study design to enrol WLHIV (n=60) who are diagnosed as having low-grade CIN (CIN1) for
a 6-monthly follow-up for 2 years to detect persistent CIN1 and progression of CIN1 to CIN2/3. The findings of
this study will be of great public health significance for 2 reasons. First, they may provide evidence of the
existence of a better performance screening method for the primary and triage detection of CIN2/3 in WLHIV.
Secondly, we may demonstrate that this high-performance test can improve the long-term predictive accuracy
of screening by extending the intervals between evaluations and thus decrease the overall cost and increase
screening uptake in WLHIV.
This application will build on the candidate’s background experience and the expertise of his team of mentors
and co-mentors in Nigeria and the US to achieve the training and research goals of this program. In the long-
term, the proposed research and training activities will provide the candidate with a unique set of experiential
skills that will enable him to transition to independence as a physician-scientist.
Public Health Relevance Statement
Project Narrative
The adoption of a validated molecular-based p16/Ki-67 dual-staining technology (DUST) protocol could
improve screening performance in women living with HIV (WLHIV) and thereby increase screening intervals
and minimize the overall cost of screening and procedure-related anxiety due to the fear of cancer. The
research proposed in this application, “COMParative ASSessment of p16/Ki-67 Dual Staining Technology in
WLHIV (COMPASS-DUST)” will aim to evaluate the performance of DUST as a new cervical cancer screening
method in WLHIV. The K43 career development program will give me access to resources to carry out the
proposed research and training activities with the guidance of established mentors and co-mentors in Nigeria
and the US, and also develop my capacity to translate the key findings from current and future studies into
public health practice application.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccreditationAcetic AcidsAddressAdoptionAdultAfricaAfrica South of the SaharaAnxietyCervicalCervical Cancer ScreeningCervical Intraepithelial NeoplasiaClient satisfactionClinicalClinical TrialsCollaborationsColposcopyComparative StudyCytologyDNADataDetectionDiagnosisDiscipline of obstetricsDiseaseEffectivenessEnrollmentEvaluationFrightFutureGoalsGrantGynecologyHIVHIV SeronegativityHIV riskHIV-1HPV-High RiskHuman PapillomavirusHuman papillomavirus 16Human papillomavirus 18Interdisciplinary StudyJournalsMalignant NeoplasmsMalignant neoplasm of cervix uteriManuscriptsMedicineMentorsMethodsMolecularNigeriaPap smearParticipantPerformancePhysiciansPositioning AttributeProceduresProgram DevelopmentProspective, cohort studyProtocols documentationPublic HealthPublic Health Applications ResearchPublic Health PracticePublicationsRecommendationResearchResearch ActivityResearch DesignResearch PersonnelResearch Project GrantsResource-limited settingResourcesRiskSamplingScientistSecureSeveritiesSpecificityStainsTechnologyTestingTimeTrainingTraining ActivityTraining ProgramsTranslatingTriageUnited StatesUniversitiesVaginaVisualWomanWorld Health OrganizationWritingagedcareercareer developmentclinical epidemiologycollegecomparativecostcost effectivenessdesigndiagnostic accuracyepidemiology studyexperiencefollow-upimprovedinnovationinterestlecturerperformance testspreventprogramsprogression riskrapid testreproductive tractresearch and developmentscreeningsexually activeskill acquisitionskillstreatment centeruptake
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
989
DUNS Number
850490315
UEI
XYJ3LWJF87N5
Project Start Date
20-July-2022
Project End Date
30-June-2027
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$100,193
Direct Costs
$92,771
Indirect Costs
$7,422
Year
Funding IC
FY Total Cost by IC
2024
National Cancer Institute
$95,184
2024
John E. Fogarty International Center for Advanced Study in the Health Sciences
$5,009
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K43TW011930-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K43TW011930-03
Patents
No Patents information available for 5K43TW011930-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K43TW011930-03
Clinical Studies
No Clinical Studies information available for 5K43TW011930-03
News and More
Related News Releases
No news release information available for 5K43TW011930-03
History
No Historical information available for 5K43TW011930-03
Similar Projects
No Similar Projects information available for 5K43TW011930-03